Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections

被引:20
作者
Low, DE
Felmingham, D
Brown, SD
Rangaraju, M
Nusrat, R
机构
[1] Univ Toronto, Dept Microbiol, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[2] GR Micro Ltd, London NW1 3ER, England
[3] CMI, Wilsonville, OR 97070 USA
[4] Aventis, F-93235 Romainville, France
[5] Aventis, Bridgewater, NJ 08807 USA
关键词
telithromycin; community-acquired pneumonia; acute exacerbations of bronchitis; acute maxillary sinusitis;
D O I
10.1016/j.jinf.2004.03.009
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives. To investigate the correlation between in vitro susceptibility of isolates and clinical outcomes with telithromycin in respiratory tract infections. Methods. The activity of telithromycin was determined by in vitro susceptibility testing of key respiratory tract pathogens isolated from patients with community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute maxillary sinusitis enrolled in 14 Phase III/IV clinical trials evaluating the clinical efficacy of telithromycin. Results. In this pooled analysis, telithromycin mode minimum inhibitory concentration (MIC) and MIC90, respectively, were: 0.016 and 0.03 mg/l against Streptococcus pneumoniae (n = 626); 0.03 and 0.5 mg/l for penicillin-resistant S. pneumoniae (n = 56); 0.03 and 1 mg/l for erythromycin-resistant S. pneumoniae (n = 81); 2 and 4 mg/l against Haemophilus influenzae (including beta-lactamase producers; n = 627); both 0.12 mg/l for Moraxella catarrhalis (n = 159); and both 0.25 mg/l for Staphylococcus aureus (n = 124). Telithromycin (5 or 7-10 days) resulted in overall clinical and bacteriologic success rates of 88.1% (1593/1808) and 89% (1593/1789), respectively. Conclusions. High levels of in vitro susceptibility to telithromycin are paralleled by high rates of clinical cure and bacteriologic eradication. (C) 2004 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:115 / 125
页数:11
相关论文
共 51 条
[31]  
LUTERMAN A, 2003, EAR NOSE THROAT, V82, P576
[32]   Community-acquired pneumonia: Epidemiology, etiology, treatment [J].
Marrie, TJ .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1998, 12 (03) :723-+
[33]  
McGuire A, 2001, Value Health, V4, P370, DOI 10.1046/j.1524-4733.2001.45049.x
[34]   Patients hospitalized after initial outpatient treatment for community-acquired pneumonia [J].
Minogue, MF ;
Coley, CM ;
Fine, MJ ;
Marrie, TJ ;
Kapoor, WN ;
Singer, DE .
ANNALS OF EMERGENCY MEDICINE, 1998, 31 (03) :376-380
[35]   Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647) [J].
Muller-Serieys, C ;
Soler, P ;
Cantalloube, C ;
Lemaitre, F ;
Gia, HP ;
Brunner, F ;
Andremont, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3104-3108
[36]   Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses [J].
Namour, F ;
Wessels, DH ;
Pascual, MH ;
Reynolds, D ;
Sultan, E ;
Lenfant, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :170-175
[37]  
NCCLS, 2001, M100S11 NCCLS, pM100
[38]   Treatment cost of acute exacerbations of chronic bronchitis [J].
Niederman, MS ;
McCombs, JS ;
Unger, AN ;
Kumar, A ;
Popovian, R .
CLINICAL THERAPEUTICS, 1999, 21 (03) :576-591
[39]   The cost of treating community-acquired pneumonia [J].
Niederman, MS ;
McCombs, JS ;
Unger, AN ;
Kumar, A ;
Popovian, R .
CLINICAL THERAPEUTICS, 1998, 20 (04) :820-837
[40]   Guidelines for the management of adults with community-acquired pneumonia - Diagnosis, assessment of severity, antimicrobial therapy, and prevention [J].
Niederman, MS ;
Mandell, LA ;
Anzueto, A ;
Bass, JB ;
Broughton, WA ;
Campbell, GD ;
Dean, N ;
File, T ;
Fine, MJ ;
Gross, PA ;
Martinez, F ;
Marrie, TJ ;
Plouffe, JF ;
Ramirez, J ;
Sarosi, GA ;
Torres, A ;
Wilson, R ;
Yu, VL .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (07) :1730-1754